ArticleChembiochem : a European journal of chemical biology2022
Genetic Survey of Psilocybe Natural Products.
Article in Chembiochem : a European journal of chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.Biomolecules · 2026Review
- Specific and Multi-Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome.Chembiochem : a European journal of chemical biology · 2026Article
- Article
- Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms.Angewandte Chemie (International ed. in English) · 2025Article
- Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.Current microbiology · 2025Review
- Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome.Chembiochem : a European journal of chemical biology · 2025Article
- Chemical Composition and Biological Activities ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.FEBS letters · 2025Article
- ExploringJournal of fungi (Basel, Switzerland) · 2025Review
- Wood-loving magic mushrooms from Australia are saprotrophic invaders in the Northern Hemisphere.Fungal systematics and evolution · 2024Article
- Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.Molecular psychiatry · 2024Article
- Unravelling the Function of the Sesquiterpene Cyclase STC3 in the Lifecycle ofInternational journal of molecular sciences · 2024Article
- Genetic regulation of L-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis.Fungal biology and biotechnology · 2024Article
- Cultivation, chemistry, and genome ofJournal of psychedelic studies · 2024Article
- Methyl transfer in psilocybin biosynthesis.Nature communications · 2024Article
- Phylogenomics of the psychoactive mushroom genusProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Bifurcate evolution of quinone synthetases in basidiomycetes.Fungal biology and biotechnology · 2023Article
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023Review
- DNA Authentication and Chemical Analysis ofApplied and environmental microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psilocybe magic mushrooms are best known for their main natural product, psilocybin, and its dephosphorylated congener, the psychedelic metabolite psilocin. Beyond tryptamines, the secondary metabolome of these fungi is poorly understood. The genomes of five species (P. azurescens, P. cubensis, P. cyanescens, P. mexicana, and P. serbica) were browsed to understand more profoundly common and species-specific metabolic capacities. The genomic analyses revealed a much greater and yet unexplored metabolic diversity than evident from parallel chemical analyses. P. cyanescens and P. mexicana were identified as aeruginascin producers. Lumichrome and verpacamide A were also detected as Psilocybe metabolites. The observations concerning the potential secondary metabolome of this fungal genus support pharmacological and toxicological efforts to find a rational basis for yet elusive phenomena, such as paralytic effects, attributed to consumption of some magic mushrooms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.